ReviewPubMed ID: 37199286·2023

Growth hormone secretagogues as potential therapeutic agents to restore growth hormone secretion in older subjects

Nass R, Gaylinn BD, Thorner MO.

Journals of Gerontology: Series A, 2023

Key finding

Despite restoring youthful GH/IGF-1 levels, MK-677 and other secretagogues have not demonstrated clinically meaningful improvements in physical function in elderly populations.

Summary

Comprehensive review of GH secretagogue research including MK-677 long-term data. Discusses the failure to translate GH/IGF-1 increases into functional improvements.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

MK-677L4

An oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. Has extensive human data but has not achieved FDA approval.

More research on MK-677

MK-677 and Alzheimer's disease: neuroprotection and cognitive decline in animal models

Journal of Alzheimer's Disease · 2012 · Animal Study

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial

Annals of Internal Medicine · 2008 · Human RCT

MK-677 and cognitive function in aged subjects: memory and executive function

European Journal of Endocrinology · 2008 · Human Pilot

MK-677 in cachexia and wasting diseases: preclinical efficacy studies

Nutrition & Metabolism · 2008 · Animal Study

MK-677 immunological effects: T-cell and B-cell function in aged subjects

Journal of Gerontology: Series A · 2007 · Human Pilot